Erika Newman named Rogel Cancer Center’s first associate director for diversity, equity, inclusion and justice

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Erika Newman was named the first associate director for diversity, equity, inclusion and justice at University of Michigan Rogel Cancer Center. 

She will lead the center’s efforts to diversify the next generation of healthcare professionals and researchers, and to champion an anti-racist and just culture within the cancer center.

“This is a really important time for these efforts,” Newman said in a statement. “We’ve had a rough year with the health disparities underscored by COVID-19 and the events that have prompted a larger racial awakening across the country, including the killings of Ahmaud Arbery and George Floyd. So, this is an opportunity for us to take a look at ourselves, to take a look at our organization, and understand how we can contribute to positive change across clinical care, research, education and training, and service to our community.”

Newman is an associate professor of pediatric surgery at Michigan Medicine.

Newman maintains a busy clinical practice with broad expertise in the care of children with solid tumors as well as a basic-science research lab that focuses on understanding tumor-specific DNA repair mechanisms as novel therapeutic options for pediatric neuroblastoma. She is surgical director of the C.S. Mott Children’s Hospital’s solid tumor oncology program.

Newman is a founding member of the Michigan Women’s Surgical Collaborative, a diverse group of academic surgeons with the mission of implementing strategies that advance women surgeons across disciplines. 

She also facilitated the development and implementation of the Michigan Promise within the Department of Surgery, a series of innovative initiatives aimed at improving faculty and resident excellence and strengthening the core culture to create a more open and inclusive environment.

Her appointment was effective June 1.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login